Early radical cystectomy can be beneficial and should be performed in patients with refractory T1 tumors or carcinoma in situ before progression to muscle invasion. In this Review I present an ...

AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression ...

The US Food and Drug Administration (FDA) has granted priority review to AstraZeneca's supplemental biologics licence ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, ...

Radical cystectomy (RC) is a morbid operation with a high rate of perioperative complications. If patients survive their cancer, long-term complications significantly impact their quality of life. Dr.

AstraZeneca AZN announced that the FDA has accepted and granted priority review to its supplemental biologics license ...

Discover a study comparing two types of treatment for bladder cancer, robot-assisted radical cystectomy and intracorporeal ...

US FDA grants priority review status to AstraZeneca’s sBLA for Imfinzi to treat patients with muscle-invasive bladder cancer: Cambridge, UK Saturday, December 7, 2024, 09:00 Hrs ...

Ferring activates first sites in a three-arm study of ADSTILADRIN as a monotherapy or in combination with chemotherapy or an ...

Cambridge: AstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and ...

Three-stage (group 2) 10 3.68 ± 0.55 Unilateral only 3.4 (MD) NS, baseline vs follow-up; NS group 1 vs 2 OE, prior cystectomy (group 2) 112 Not reported but all <6 cm 19.60 7.9 ± 4.2 Tubal ...

The durvalumab arm showed a 32% decrease in the risk of disease progression, recurrence, not undergoing radical cystectomy, or death and a 25% reduction in the risk of death compared with the ...